Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors

Completed · Phase 1

Conditions studied: Carcinoma, Non-Small-Cell Lung, Mesothelioma, Bladder Cancer, Ovarian Cancer, Peritoneal Cancer, Thymoma, Thymus Cancer, Uterine Cervical Cancer

In brief

This study will determine the maximum-tolerated dose (MTD) for oral bosutinib when used in combination with pemetrexed. The MTD is the highest dose of bosutinib with pemetrexed that can be given without causing severe side effects. This study will also test the safety of this combination and see what effects (good or bad) it has on participants and their cancer.

Key facts

Study ID

NCT03023319

Run by

Nagla Abdel Karim

People needed

6

Starts

2019-12-10

Expected to finish

2022-05-10

Last updated by the study team

2022-06-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Pathologically or cytologically proven advanced, metastatic non-squamous non-small cell lung cancer, pleural malignant mesothelioma, bladder or urethral cancer, ovarian cancer, primary peritoneal cancer, thymoma and thymic cancer and uterine cervical cancer.
• Measurable disease
• Life expectancy of greater than 3 months.
• Ability to take folic acid, vitamin B12, and dexamethasone according to protocol.

You may not qualify if…

• Untreated or symptomatic brain metastases.

Where it is running

• Augusta University Georgia Cancer Center — Augusta, Georgia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.